Recent Updates
Recently added Catalysts
LRMR Positive Sentiment

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Wednesday, March 6, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Larimar Therapeutics, a clinical-stage biotechnology company, announced that its management team will present at the Leerink Partners Global Biopharma Conference in Miami Beach, FL, from March 11 to 13, 2024. The presentation will include participation in 1x1 investor meetings, aimed at increasing engagement with investors. The company continues to focus on treatments for complex rare diseases, such as Friedreich's ataxia, with its lead compound, nomlabofusp. A webcast of the presentation will be available for replay on Larimar's website for 30 days post-event.
Price reaction · baseline $11.5 (2024-03-05 close) · hit after-hours · 1 other LRMR headline(s) in the window, move may be shared
day 0 close
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Larimar Therapeutics is presenting at a significant investor conference.
  • Participation in 1x1 investor meetings may enhance investor interest.
  • Focus on developing treatments for complex rare diseases is commendable.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
18%
average across 3 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
ZGN-1061
Phase 2 · Type 2 Diabetes Mellitus

Full Press Release Details

BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Biopharma Conference, taking place in Miami Beach, FL from March 11 – 13, 2024.
Details on the presentation can be found below.
Date: Wednesday, March 13, 2024
Webcast Link: https://wsw.com/webcast/leerink33/lrmr/2241008
Following the conclusion of the presentation, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Frequently Asked Questions

When is the Leerink Partners Global Biopharma Conference?

The conference is scheduled from March 11 to 13, 2024.

How can I view Larimar's presentation?

Larimar's presentation can be viewed via a webcast on March 13, 2024.

What is nomlabofusp used for?

Nomlabofusp is being developed as a treatment for Friedreich's ataxia.

How long will the presentation replay be available?

The replay will be accessible for 30 days after the presentation.

What diseases does Larimar Therapeutics target?

Larimar focuses on treatments for complex rare diseases.

ShareAdd on Google
Tags: LRMR Viatris Investor Conferences Healthcare biotechnology Friedreich's ataxia Leerink Partners clinical-stage
Last updated: Mar 6, 2024

Biotech snapshot

Cash runway
$156M liquidity · $15M/mo burn
~10 mo
Medium dilution risk
Lead asset
ZGN-1061Phase 2
Type 2 Diabetes Mellitus →

Catalyst track record

+56%
best trade around LRMR's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for LRMR.

See every catalyst's timing & PoA →